Cost-Effectiveness of Adjuvant Osimertinib With and Without Chemotherapy for Surgically Resected NSCLC
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Introduction: mutations. Nevertheless, this treatment is lengthy and expensive. Its cost-effectiveness profile as monotherapy versus combination with chemotherapy is unknown. In this context, we investigate the cost-effectiveness of adjuvant osimertinib with and without chemotherapy for NSCLC. Methods: A set of Markov models was established to predict the cost-effectiveness of these different regimens. Data were sourced from the ADAURA trial's publications and protocols. Health outcomes were quantified as quality-adjusted life-years (QALYs). Costs and incremental cost-effectiveness ratios (ICERs) were estimated in U.S. dollars (USD) and USD per QALY, respectively. Deterministic and probabilistic sensitivity analyses were performed. Data from the Surveillance, Epidemiology, and End Results Program were used to predict additional costs to the U.S. health care system. Results: Compared with treatment with chemotherapy alone, treatment with osimertinib plus chemotherapy yielded 5.86 QALYs with incremental costs of $414,607.69 (ICER = $380,347.85 per QALY). Treatment with osimertinib alone yielded 6.63 QALYs with an incremental cost of $402,224.32 (ICER = $213,447.59 per QALY). Osimertinib is only likely to be cost-effective if the willingness-to-pay threshold per QALY is $200,000 or more. The price of osimertinib had the strongest influence on cost-effectiveness. On the basis of Surveillance, Epidemiology, and End Results Program data, these practices may cost the U.S. health care system an additional 8.9 billion USD/year. Conclusions: Adjuvant osimertinib alone is more cost-effective than combination therapy, but only if the willingness-to-pay is high. A reduction in the price of osimertinib would improve its cost-effectiveness profile.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Cost-Effectiveness of Adjuvant Osimertinib With and Without Chemotherapy for Surgically Resected NSCLC
- Date Crossref
- 01/06/2025
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Loyola University Chicago pays non établi dans la noticeUniversité ou école supérieure
-
Loyola University Medical Center Department of Thoracic & CV Surgery pays non établi dans la noticeÉtablissement de santé
-
University of Illinois Chicago pays non établi dans la noticeUniversité ou école supérieure
-
Mayo Clinic Department of Surgery pays non établi dans la noticeÉtablissement de santé
-
Jr. VA Hospital Edward Hines pays non établi dans la noticeÉtablissement de santé
-
Stritch School of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
University of Illinois at Chicago Department of Surgery pays non établi dans la noticeUniversité ou école supérieure
-
Edward Hines Jr. Medical Center Department of Surgery pays non établi dans la noticeÉtablissement de santé
Loyola University Chicago, Department of Thoracic & CV Surgery — Loyola University Medical Center et University of Illinois Chicago, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.